$44.2MSeries C, 15 October 2025
Funds support clinical development of dencatistat across several cancer indications.
- Amount
- $44.2M
- Stage
- Series C
- Announced
- 15 October 2025
- Lead
- V-Bio Ventures
- Other investors
- Pontifax, Bpifrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative
- Use of funds
- Funds support clinical development of dencatistat across several cancer indications.
- Checked
- Announced by the company
- Sources
- Step Pharma raises 38M euros Series C led by V-Bio Ventures biospace.com
Step Pharma raises 38M euros Series C led by V-Bio Ventures maddyness.com